Colon cancer is getting younger. Watch out for these symptoms to help lower your risk.

Colon cancer has been named the deadliest cancer in the US, with deaths and diagnoses rising among people under 50 and the trend described as "going in the wrong direction." Researchers suspect an environmental or behavioral exposure introduced in the latter half of the 20th century may be driving the increase, but the cause remains unclear. Business Insider highlights the financial and career impacts for younger patients and points readers to screening, risk-reduction, and patient-cost resources.

Analysis

A persistent shift in incidence among a different demographic cohort is a demand shock that should rewire where dollars flow in GI oncology: from procedure-led, facility-based revenue toward decentralized diagnostics, lab capacity and digital triage. Expect near-term revenue elasticity: if payers broaden coverage or employers adopt screening mandates, non-invasive test volumes can grow double-digits within 6–12 months because capacity scale (labs, automated platforms, logistics) is the binding constraint, not raw clinical need.

Second-order supply effects matter more than headline winners. Lab-reagent supply, high-throughput sequencing capacity, and single-use scope manufacturing will see asymmetric upside as providers try to meet new screening flow; conversely, outpatient procedural centers with fixed-cost endoscopy suites will face margin pressure if a material share of asymptomatic screens convert to at-home tests rather than direct scopes. A binary regulatory/payer event (USPSTF/CMS coverage expansion or a major NCD for liquid biopsy) is the highest-conviction catalyst and would re-rate diagnostics names within 3–12 months.

Tail risks: if a clear, modifiable environmental cause is identified and addressed by public health policy, incidence could materially reverse over years, compressing the long-term TAM for early-detection players. For portfolios, the asymmetric payoff favors owning scalable lab/platform exposures via option-levered positions while hedging binary reimbursement or scientific-failure risk; operational risks (lab build delays, reagent shortages) create tactical windows to scale into positions at lower cost.

Key Decisions for Investors

• Buy Exact Sciences (EXAS) — 6–12 month horizon. Tactical entry on a sub-10% pullback; size to 2–3% of equity book. Rationale: incumbent retail stool-DNA player with distribution reach; if private/public payers broaden coverage, expect 30–60% upside in 6–12 months from volume reacceleration. Risk: -30% downside on adverse reimbursement or quality-control hits; maintain a 30% stop-loss or hedge with 6–9 month protective puts sized to 25% of position.
• Long Guardant Health (GH) — 12–24 month horizon via 18–24 month LEAP calls (or 50% cash/50% options if volatile). Thesis: liquid biopsy can capture incremental share as demand shifts to non-invasive detection and as sequencing utility expands; upside ~2x on favorable payer NCD/validation data. Tail risk: binary clinical/payer failure that could drive near-total option loss; size accordingly.
• Relative trade: Pair long EXAS / short HCA Healthcare (HCA) — 6–18 months. Structure 60/40 notional; expectation that at-home and stool-based screening growth partially substitutes elective screening colonoscopies, pressuring outpatient endoscopy utilization and margins at high-fixed-cost hospital operators. Target 20–30% pair return; risk if endoscopy volumes hold or therapeutic colonoscopy demand rises, cap losses at 15% via stop rules.
• Protective hedge: Allocate 0.5–1% of portfolio to puts on leading diagnostics (e.g., EXAS) or buy a short-dated index-protective position tied to healthcare diagnostics ETFs for 6–12 months. Use this to offset a binary reimbursement or sudden epidemiological reversal triggered by etiologic discovery.